title: Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.
abstract: Estrogen receptor (ER) status in breast cancer is currently the most important predictive biomarker that determines breast cancer prognosis after treatment with endocrine therapy. Although immunohistochemistry has been widely viewed as the gold standard methodology for ER testing in breast cancer, lack of standardized procedures, and lack of regulatory adherence to testing guidelines has resulted in high rates of "false-negative" results worldwide. Standardized testing is only possible after all aspects of ER testing--preanalytical, analytical, and postanalytical, have been closely controlled. A meeting of the "ad-hoc committee" of expert pathologists, technologists, and scientists, representing academic centers, reference laboratories, and various agencies, issued standardization testing recommendations, aimed at optimization of clinical ER testing environment, as a step toward improved standardized testing.
authors.affiliation: Vitro Molecular Laboratories, Miami, FL daggerKeck School of Medicine, University of Southern California, Los Angeles, USA. vitromolecular@mac.com
authors.forename: Hadi
authors.initials: H
authors.lastname: Yaziji
authors.forename: Clive R
authors.initials: CR
authors.lastname: Taylor
authors.forename: Neal S
authors.initials: NS
authors.lastname: Goldstein
authors.forename: David J
authors.initials: DJ
authors.lastname: Dabbs
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Hammond
authors.forename: Bryan
authors.initials: B
authors.lastname: Hewlett
authors.forename: Alton D
authors.initials: AD
authors.lastname: Floyd
authors.forename: Todd S
authors.initials: TS
authors.lastname: Barry
authors.forename: Alvn W
authors.initials: AW
authors.lastname: Martin
authors.forename: Sunil
authors.initials: S
authors.lastname: Badve
authors.forename: Frederick
authors.initials: F
authors.lastname: Baehner
authors.forename: Richard W
authors.initials: RW
authors.lastname: Cartun
authors.forename: Richard N
authors.initials: RN
authors.lastname: Eisen
authors.forename: Paul E
authors.initials: PE
authors.lastname: Swanson
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hewitt
authors.forename: Mogen
authors.initials: M
authors.lastname: Vyberg
authors.forename: David G
authors.initials: DG
authors.lastname: Hicks
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D003951:Diagnostic Errors / Q000517:prevention & control; D004797:Enzyme-Linked Immunosorbent Assay / Q000592:standards; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods* / Q000592:standards*; D011960:Receptors, Estrogen / Q000378:metabolism*; D012680:Sensitivity and Specificity; D013048:Specimen Handling / Q000592:standards; D013629:Tamoxifen / Q000008:administration & dosage; D016707:Tissue Fixation / Q000592:standards
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D013629:Tamoxifen